Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025
Ascendis Pharma A/S (NASDAQ: ASND) is back in the spotlight on December 9, 2025, after its share price slipped again while Wall Street continues to project hefty upside and label the name a “Buy” or “Strong Buy.” The Danish biotech, known for its TransCon long-acting prodrug platform and endocrine rare disease franchise, is wrestling with three forces at once: Let’s unpack what’s going on with Ascendis Pharma stock today, how the story changed in recent weeks, and what current forecasts say about where ASND could go next. ASND stock today: price action and context By late trading on December 9,
